An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation

Laboratory Investigation

Volumn 87, Issue 11, 2007, Pages 1092-1102

  Perrin, George Q ^a,b   Li, Hua ^a   Fishbein, Lauren ^a   Thomson, Susanne A ^a   Hwang, Min S ^c   Scarborough, Mark T ^a   Yachnis, Anthony T ^a   Wallace, Margaret R ^a   Mareci, Thomas H ^a   Muir, David ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c University of Florida   (United States)

Author keywords

Angiogenesis; Malignant peripheral nerve sheath tumor; Neurofibromatosis; Orthotopic; Steroid hormone; Xenografts

Indexed keywords

ESTROGEN; PROGESTERONE; STEROID HORMONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER TRANSPLANTATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENGRAFTMENT; ESTROGEN ACTIVITY; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; ORTHOTOPIC TRANSPLANTATION; OVARIECTOMY; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REPRODUCIBILITY; SCHWANN CELL; SCIATIC NERVE; SCID MOUSE; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 35348997092     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700675     Document Type: Article

References (56)

1. Friedman JM, Gutmann DH, MacCollum M, et al (eds). Neurofibromatosis: Phenotype, Natural History and Pathogenesis, 3rd edn. The Johns Hopkins Press: Baltimore, MD, 1999.
2. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 1999;89:23-30.
3. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumor. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-2021.
4. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-314.
5. Korf BR. Neurofibromas and malignant tumors of the peripheral nerve sheath. In: Friedman JM, Gutmann DH, MacCollum M, Riccardi VM (eds). Neurofibromatosis: Phenotype, Natural History and Pathogenesis, 3rd edn. The Johns Hopkins Press: Baltimore, MD, 1999, pp 142-161.
6. Scheithauer BW, Woodruff JM, Erlandson RA. Tumors of the peripheral nervous system. In: Rosai J, Sobin LH (eds). Atlas of Tumor Pathology. Series 3, Fascicle 24. Armed Forces Institute of Pathology: Washington, DC, 1997, pp 385-405.
7. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev Rev 1994;8:1019-1029.
8. Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994;7:353-361.
9. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286:2172-2176.
10. Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science 1999;286:2176-2179.
11. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-922.
12. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007;15:279-286.
13. Hirokawa Y, Nakajima H, Hanemann CO, et al. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther 2005;4:379-381.
14. Hirokawa Y, Nheu T, Grimm K, et al. Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice. Cancer Biol Ther 2006;5:305-309.
15. Muir D, Neubauer D, Lim IT, et al. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001;158:501-513.
16. Perrin G, Fishbein L, Thomson S, et al. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res 2007;85:1347-1357.
17. Riccardi VM. Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr 1992;22:66-106.
18. McLaughlin ME, Jacks T. Progesterone receptor expression in neurofibromas. Cancer Res 2003;63:752-755.
19. Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 1996;66:7-10.
20. Messerli SM, Tang Y, Giovannini M, et al. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 2002;4:501-509.
21. Banerjee D, Hegedus B, Gutmann DH, et al. Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage 2007;35:1434-1437.
22. Rosenbaum T, Engelbrecht V, Krolls W, et al. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev 1999;21:268-273.
23. Chang LS, Jacob A, Lorenz M, et al. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope 2006;116:2018-2026.
24. Gutmann DH, Aynsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57.
25. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90-92.
26. Wallace MR, Rasmussen SA, Lim IT, et al. Culture of cytogenetically abnormal Schwann cells from benign and malignant NF1 tumors. Genes Chromosomes Cancer 2000;27:117-123.
27. Abernathy CR, Rasmussen SA, Stalker HJ, et al. NF1 mutation analysis using a combined heteroduplex/SSCP approach. Hum Mutat 1997;9:548-554.
28. Rasmussen SA, Colman SD, Ho VT, et al. Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet 1998;35:468-471.
29. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci USA 1996;93:10285-10290.
30. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol 2000;190:31-38.
31. Rasmussen SA, Overman J, Thomson SA, et al. Chromosome 17 loss of heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000;28:425-431.
32. Fishbein L, Zhang X, Fisher LB, et al. In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells. Mol Carcinogen 2007;46:512-523.
33. Aagaard BD, Lazar DA, Lankerovich L, et al. High resolution magnetic resonance imaging is a noninvasive method or observing injury and recovery in the peripheral nervous system. Neurosurgery 2003;53:199-204.
34. Grant GA, Britz GW, Goodkin R, et al. The utility of magnetic resonance imaging in evaluating peripheral nerve disorders. Muscle Nerve 2002;25:314-331.
35. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrastenhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
36. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
37. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004;64:3718-3724.
38. Schwarz J, Belzberg AJ. Malignant peripheral nerve sheath tumors in the setting of segmental neurofibromatosis. Case report. J Neurosurg 2000;92:342-346.
39. Vogel KS, Brannan CI, Jenkins NA, et al. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 1995;82:733-742.
40. Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 1997;17:862-872.
41. Sheela S, Riccardi VM, Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 1990;111:645-653.
42. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-597.
43. Medved M, Karczmar G, Yang C, et al. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. J Magn Reson Imaging 2004;20:122-128.
44. Mautner VF, Friedrich RE, von Deimling A, et al. Malignant peripheral nerve sheath tumors in neurofibromatosis type 1: MRI supports the diagnosis of malignant peripheral nerve sheath tumor. Neuroradiology 2003;45:618-625.
45. Dorshkind K, Keller GM, Phillips RA, et al. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 1984;132:1804-1808.
46. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18.
47. Ribatti D, Crivellato E, Roccaro AM, et al. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004;34:1660-1664.
48. Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995;147:564-573.
49. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992;3:73-79.
50. Yang F-C, Ingram DA, Chen S, et al. Neurofibromin-deficient Schwann cells secrete potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 2003;112:1851-1861.
51. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001;194:57-69.
52. Ryan JJ, Klein KA, Neuberger TJ, et al. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 1994;37:415-432.
53. Viskochil DH. It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. J Clin Invest 2003;112:1791-1793.
54. Lammert M, Mautner V-F, Kluwe L. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC Cancer 2005;5:16-19.
55. Puls LE, Chandler PA. Malignant schwannoma in pregnancy. Acta Obstet Gynecol Scand 1991;10:243-244.
56. Posma E, Aalbers R, Kurniawan KS, et al. Neurofibromatosis type I and pregnancy: a fatal attraction? Development of malignant schwannoma during pregnancy in a patient with neurofibromatosis type I. BJOG 2003;110:530-532.